Skip to main content

Remote Job Finders (RJF)

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

It’s official: FDA Commissioner Marty Makary is out at the FDA after reports of his ouster emerged late last week; Sanofi is reportedly having challenges with one of the FDA’s new signature programs; and biopharma CEOs’ multimillion-dollar salaries ticked up again this year. Who made the most in 2025?

Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?

European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.

Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site

Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.
Scroll to top